# **List of Resources**

Cancer Risk and Genetics	2
Cancer Screening	
Screening Options	2
Guidelines by Gene	2
Screening Clinical Research Studies	2
Treatment	
Treatment Options	3
Treatment Research	3
Support	3
Public Policy	
FORCE Public Policy	4
Partner Public Policy	4
More FORCE Partners	4
Additional Resources	
Glossary of Terms	4
Feedback Survey	4
Webinar Slides	4

# **Hereditary Prostate Cancer Resources**

#### **Cancer Risk and Genetics**

- How to Get Genetic Testing
- <u>Sharing Health Information with Relatives</u>
- Genetic Testing for People Diagnosed with Prostate Cancer
- Find a Genetic Counselor
- Hereditary Prostate Cancer Risk



## **Prostate Cancer Screening**

- Prostate Cancer Screening Options
- Prostate Cancer Screening Guidelines



- Cancer screening guidelines by gene
  - o ATM
  - o BRCA1
  - o BRCA2
  - o CHEK2
  - o <u>EPCAM</u>
  - o <u>HOXB13</u>

- o MLH1
- o MSH2
- o MSH6
- o PALB2
- o PMS2
- o TP53



- Prostate cancer screening research
  - Prostate Cancer Screening for People
     AT Genetic Risk FOr Aggressive Disease
  - Screening for Men at High Genetic
     Risk for Prostate Cancer
  - MRI Screening in Men at High Risk of Developing Prostate Cancer
  - Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
  - o Upright MRI for Prostate Cancer Screening
  - Biparametric MRI as a Screening Tool for Prostate Cancer in a High-Risk Cohort



#### **Prostate Cancer Treatment**

- Hereditary Prostate Cancer Treatment Information
- Prostate Cancer Stages and Grades
- Treatment Options for Prostate Cancer
- Biomarker Testing
- Genetic Testing
- Targeted and Immunotherapies



## Prostate cancer treatment research

- NePtune Study Listing: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
- o <u>NePtune Blog: Investigating A New Approach to Prostate</u>
  Cancer Treatment in Mutation Carriers
- Saruparib vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)
- o MEVPRO: Pfizer Clinical Trials for Metastatic Prostate Cancer
- A Study of SYNC-T Therapy SV-102 in Participants with Metastatic Castration-Resistant Prostate Cancer (Legion-100)
- PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved
   Survival and Treatment Effectiveness
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted
   Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
- Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

#### **Prostate Cancer Support**

- FORCE support programs
  - o Peer Navigation Program
  - o Support Meetings
  - Message Boards
  - Private FaceBook Group
- ZERO360 Helpline
- ZERO Online Peer Support





# **Public Policy**

- FORCE Policy Priorities
  - o FORCE Federal Policy Initiatives
  - o FORCE State Policy Initiatives
  - o Get Involved



- o ZERO Prostate Cancer Policy Priorities
- o 2026 ZERO Prostate Cancer Advocacy Summit
- o National Coalition for Cancer Survivorship Public Policy



- ANCAN
- Cancer Support Community
- Male Care
- Michigan Men's Health Foundation
- Patient Advocate Foundation
- Prostate Conditions Education Council
- Triage Cancer
- ZERO Prostate Cancer



### **Additional Resources**

**FORCE Glossary of Terms** 



**Feedback Survey** 



**Webinar Slides** 

